Astrazeneca PLC (AZN) : Investors lapped up stocks on upticks to the tune of $15.44 million in the Tuesdays trading session. The trading value on downticks was comparatively at $7.23 million and the uptick to downtick ratio of 2.13 indicates continuous buying by the bulls. The net money flow into the stock was $8.2 million. The block trades were dominated by the bulls with a healthy 3.79, uptick to downtick ratio. Only $2.24 million worth of trades exchanged hands on downticks showing the reluctance of the large traders to part with their holdings. Upticks saw transactions worth $8.5 clearly indicating buying by large investors. The total money flow for block trades stood at $6.26 million, which is a positive for the stock in the long-term. Astrazeneca PLC (AZN) fell $0.03 during the day at $29.95, a drop of -0.08% over the previous days close. However, for the week, the stock is -0.55%, compared to the previous week.
Institutional Investors own 10.17% of Astrazeneca PLC shares.
Shares of AstraZeneca PLC rose by 0.17% in the last five trading days and 7.97% for the last 4 weeks. AstraZeneca PLC is up 3.53% in the last 3-month period. Year-to-Date the stock performance stands at -8.17%.
Astrazeneca PLC (NYSE:AZN): stock turned positive on Tuesday. Though the stock opened at $29.87, the bulls momentum made the stock top out at $30.31 level for the day. The stock recorded a low of $29.83 and closed the trading day at $30.2, in the green by 0.77%. The total traded volume for the day was 11,359,333. The stock had closed at $29.97 in the previous days trading.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).